naxitamab sold brand name danyelza anticancer medication monoclonal antibody used combination granulocytemacrophage colonystimulating factor gmcsf people one year age older relapsed refractory highrisk neuroblastoma bone bone marrow demonstrating partial response minor response stable disease prior common adverse reactions include injection site reactions infusionrelated reactions pain tachycardia fast heart beats vomiting cough nausea diarrhea decreased appetite hypertension fatigue erythema multiforme peripheral neuropathy urticaria pyrexia headache injection site reaction edema anxiety localized edema us food drug administration fda granted application naxitamab priority review breakthrough therapy orphan drug fda issued priority review voucher rare pediatric disease product later granted priority naxitamab used combination granulocytemacrophage colonystimulating factor gmcsf treat people one year age older highrisk neuroblastoma bone bone marrow whose tumor respond come back previous treatments shown partial response minor response stable disease prior application naxitamab approved based two clinical trials trial trial participants highrisk neuroblastoma bone bone trials conducted four centers united states trials enrolled participants previously treated highrisk neuroblastoma bone bone participants responding previous therapies anymore participants experienced return participants cancer actively growing last therapy included participants received naxitamab combination granulocytemacrophage colonystimulating factor gmcsf according trial naxitamab approved medical use united states november antineoplastic immunomodulatory drug article stub help wikipedia expanding monoclonal article stub help wikipedia expanding ithttpsenwikipediaorgwikinaxitamab